{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:02:13Z","timestamp":1791849733912,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004263","name":"FAPERGS","doi-asserted-by":"crossref","award":["03\/2017"],"award-info":[{"award-number":["03\/2017"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Duloxetine and amitriptyline are antidepressants used in the treatment of fibromyalgia. In published systematic reviews, there is no agreement about which drug is more effective and safer. This study aimed to compare evidence of the efficacy and safety of duloxetine compared with amitriptyline in the treatment of adult patients with fibromyalgia. This work contributes to guiding clinicians on the use of duloxetine or amitriptyline for the treatment of fibromyalgia and provides information for public health decision-makers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Overview of systematic reviews of clinical trials comparing duloxetine and amitriptyline in the treatment of fibromyalgia. The reviews were screened in Cochrane, PubMed, EMBASE, and SRDR with no restrictions on language and year of publication, considering that the research was conducted in July 2018 and updated until May 2020. The selection was based on the following criteria: adult patients with a diagnosis of fibromyalgia treated with duloxetine or amitriptyline, comparing the efficacy and safety in pain, fatigue, sleep, and mood disorder symptoms and quality of life, in addition to the acceptability of these antidepressants. The methodological quality and strength of evidence were assessed using the AMSTAR and GRADE instruments.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Eight systematic reviews were selected. Amitriptyline had low evidence for pain, moderate evidence for sleep and fatigue, and high evidence for quality of life. Duloxetine had high quality of evidence in patients with mood disorders. With low evidence, duloxetine has higher acceptability, but is safer in older patients, while amitriptyline is safer for non-elderly individuals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Both antidepressants are effective in the treatment of fibromyalgia, differing according to the patient\u2019s symptoms and profile.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Registration<\/jats:title>\n<jats:p>PROSPERO: CRD42019116101.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s42358-020-00137-5","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T13:03:51Z","timestamp":1594213431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews"],"prefix":"10.1186","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-1193","authenticated-orcid":false,"given":"\u00c1urea Dias","family":"de Farias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia Alves","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane","family":"da Silva Dal Pizzol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"issue":"1","key":"137_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/S0482-50042010000100006","volume":"50","author":"RE HEYMANN","year":"2010","unstructured":"HEYMANN RE, PAIVA E, HELFENSTEIN M, POLLAK D, MARTINEZ J, PROVENZA JR, et al. Brazilian consensus on the treatment of fibromyalgia. Brazilian J Rheumatol. 2010;50(1):56\u201366Available from. https:\/\/doi.org\/10.1590\/S0482-50042010000100006.","journal-title":"Brazilian J Rheumatol"},{"key":"137_CR2","doi-asserted-by":"publisher","unstructured":"QUEIROZ LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. Available from https:\/\/doi.org\/10.1007\/s11916-013-0356-5. Accessed 18 Mar 2019.","DOI":"10.1007\/s11916-013-0356-5"},{"key":"137_CR3","unstructured":"SENNA ER, PEREIRA VB, CICONELLI RM, FERRAZ MB. Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach. J Rheumatol. 2020:5 Available from: http:\/\/www.jrheum.org\/content\/31\/3\/594."},{"key":"#cr-split#-137_CR4.1","unstructured":"CHAKR R, Xavier R. Fibromyalgia: practical principles that assist in the indication and adjustment of drug treatment. J Bras Med. 2014;102"},{"key":"#cr-split#-137_CR4.2","unstructured":"(6) [cited 2019 Mar 31]. Available from: https:\/\/pesquisa.bvsalud.org\/portal\/resource\/pt\/lil-737128."},{"issue":"2","key":"137_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/jama.2008.944","volume":"301","author":"W H\u00c4USER","year":"2009","unstructured":"H\u00c4USER W, BERNARDY K, \u00dc\u00c7EYLER N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301(2):198Available from. https:\/\/doi.org\/10.1001\/jama.2008.944.","journal-title":"JAMA"},{"issue":"6","key":"137_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1533-2500.2010.00441.x","volume":"11","author":"NS ROSKELL","year":"2011","unstructured":"ROSKELL NS, BEARD S, ZHAO Y, KIM LE TK. A meta-analysis of pain response in the treatment of fibromyalgia. Meta-analysis of fibromyalgia treatments. Pain Pract. 2011;11(6):516\u201327. https:\/\/doi.org\/10.1111\/j.1533-2500.2010.00441.x.","journal-title":"Pain Pract"},{"issue":"8","key":"137_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1517\/14656566.7.8.1027","volume":"7","author":"RL ROBINSON","year":"2006","unstructured":"ROBINSON RL, JONES ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7(8):1027\u201339Available from:. https:\/\/doi.org\/10.1517\/14656566.7.8.1027.","journal-title":"Expert Opin Pharmacother"},{"key":"137_CR8","unstructured":"HORSLEY W. Cost comparison charts. RDTC. 2020;78. Available from: http:\/\/gmmmg.nhs.uk\/docs\/cost_comparison_charts.pdf. [cited 2020 Jun 05]."},{"key":"137_CR9","doi-asserted-by":"publisher","unstructured":"RICHARDSON J, Schlander M. Health technology assessment (HTA) and economic evaluation: efficiency or fairness first. Journal of Market Access & Health Policy. 2019;7(1):1557981. https:\/\/doi.org\/10.1080\/20016689.2018.1557981.","DOI":"10.1080\/20016689.2018.1557981"},{"key":"137_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jclinepi.2017.10.002","volume":"93","author":"KI BOUGIOUKAS","year":"2018","unstructured":"BOUGIOUKAS KI, LIAKOS A, TSAPAS A, NTZANI E, Haidich A. Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2018;93:9\u201324. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.10.002.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"137_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-018-0695-8","volume":"7","author":"H HUNT","year":"2018","unstructured":"HUNT H, POLLOCK A, CAMPBELL P, ESTCOURT L, BRUNTON G. An introduction to overviews of reviews: planning a relevant research question and objective for an overview. Syst Rev. 2018;7(1):39. https:\/\/doi.org\/10.1186\/s13643-018-0695-8.","journal-title":"Syst Rev"},{"key":"137_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.ch22","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated march 2011]. The Cochrane collaboration","author":"LA BECKER","year":"2011","unstructured":"BECKER LA, Oxman AD. Chapter 22: overviews of reviews. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated march 2011]. The Cochrane collaboration; 2011Available from: www.cochrane-handbook.org. https:\/\/doi.org\/10.1002\/9780470712184.ch22."},{"key":"137_CR13","doi-asserted-by":"publisher","unstructured":"SHEA BJ, REEVES BC, WELLS G, THUKU M, HAMEL C, MORAN J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both. BMJ. 2017;j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","DOI":"10.1136\/bmj.j4008"},{"key":"137_CR14","unstructured":"SCH\u00dcNEMANN H, BROZEK J, GUYATT G, OXMAN A. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE working group; 2013. Available from: guidelinedevelopment.org\/handbook."},{"key":"137_CR15","volume-title":"GRADEpro guideline development tool [software]","author":"GRADEpro GDT","year":"2015","unstructured":"GRADEpro GDT. GRADEpro guideline development tool [software]; 2015. McMaster University, (developed by Evidence Prime, Inc.). Available from: gradepro.org."},{"issue":"4","key":"137_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D PIEPER","year":"2014","unstructured":"PIEPER D, Antoine S-L, MATHES T, NEUGEBAUER EAM, EIKERMANN M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.11.007.","journal-title":"J Clin Epidemiol"},{"key":"137_CR17","doi-asserted-by":"publisher","unstructured":"FARAG H, YUNUSA I, GOSWAMI H, SULTAN I, DOUCETTE J, Eguale T. Effectiveness and acceptability of amitriptyline and food and drug administration \u2013 approved treatments for fibromyalgia: a network meta-analysis [abstract]. Value Health. 2020;23(supplement 1). https:\/\/doi.org\/10.1016\/j.jval.2020.04.693.","DOI":"10.1016\/j.jval.2020.04.693"},{"key":"137_CR18","doi-asserted-by":"publisher","unstructured":"THORPE J, SHUM B, MOORE RA, WIFFEN PJ, GILRON I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane database of systematic reviews. 2018. Available from: https:\/\/doi.org\/10.1002\/14651858.CD010585.pub2. [cited 2019 May 26].","DOI":"10.1002\/14651858.CD010585.pub2"},{"issue":"3","key":"137_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00482-017-0207-0","volume":"31","author":"C SOMMER","year":"2017","unstructured":"SOMMER C, ALTEN R, K-J B\u00c4R, BERNATECK M, BR\u00dcCKLE W, FRIEDEL E, et al. Drug therapy of fibromyalgia syndrome. Updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):274\u201384. https:\/\/doi.org\/10.1007\/s00482-017-0207-0.","journal-title":"Schmerz"},{"key":"137_CR20","volume-title":"Drug class review: drugs for fibromyalgia: final original report","author":"B SMITH","year":"2011","unstructured":"SMITH B, Peterson K, Fu R, McDonagh M, Thakurta S. Drug class review: drugs for fibromyalgia: final original report. Portland: Oregon Health & Science University; 2011. Accessed on: 27 Nov 2018. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK55552\/."},{"issue":"3","key":"137_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","volume":"50","author":"W H\u00c4USER","year":"2011","unstructured":"H\u00c4USER W, PETZKE F, \u00dc\u00c7EYLER N, SOMMER C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta- analysis. Rheumatology. 2011;50(3):532\u201343. https:\/\/doi.org\/10.1093\/rheumatology\/keq354.","journal-title":"Rheumatology"},{"issue":"9","key":"137_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/art.24000","volume":"59","author":"N \u00dc\u00c7EYLER","year":"2008","unstructured":"\u00dc\u00c7EYLER N, H\u00c4USER W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279\u201398. https:\/\/doi.org\/10.1002\/art.24000.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"137_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/rheumatology\/ken110","volume":"47","author":"S PERROT","year":"2008","unstructured":"PERROT S, R-M JAVIER, MARTY M, LE JEUNNE C, LAROCHE F, the CEDR (Cercle d\u2019Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology. 2008;47(8):1117\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/ken110.","journal-title":"Rheumatology"},{"issue":"2","key":"137_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2017-211587","volume":"76","author":"GJ MACFARLANE","year":"2017","unstructured":"MACFARLANE GJ, KRONISCH C, DEAN LE, ATZENI F, H\u00c4USER W, Fiub E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318\u201328Available from. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211587.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"137_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/918216","volume":"18","author":"FITZCHARLES M-A","year":"2013","unstructured":"M-A FITZCHARLES, STE-MARIE PA, GOLDENBERG DL, PEREIRA JX, ABBEY S, CHOINI\u00c8RE M, et al. 2012 Canadian guidelines for the diagnosis and Management of Fibromyalgia Syndrome: executive summary. Pain Res Manag. 2013;18(3):119\u201326. https:\/\/doi.org\/10.1155\/2013\/918216.","journal-title":"Pain Res Manag"},{"issue":"2","key":"137_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/bf02908299","volume":"21","author":"LA ROSSY","year":"1999","unstructured":"ROSSY LA, BUCKELEW SP, DORR N, HAGGLUND KJ, THAYER JF, MCINTOSH MJ, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21(2):180\u201391. https:\/\/doi.org\/10.1007\/bf02908299.","journal-title":"Ann Behav Med"},{"key":"137_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuroscience.2016.06.006","volume":"338","author":"KA SLUKA","year":"2016","unstructured":"SLUKA KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114\u201329. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.06.006.","journal-title":"Neuroscience"},{"issue":"5","key":"137_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11916-011-0213-3","volume":"15","author":"S ROIZENBLATT","year":"2011","unstructured":"ROIZENBLATT S, NETO NSR, Tufik S. Sleep disorders and fibromyalgia. Curr Pain Headache Rep. 2011;15(5):347\u201357Available from. https:\/\/doi.org\/10.1007\/s11916-011-0213-3.","journal-title":"Curr Pain Headache Rep"},{"key":"137_CR29","unstructured":"LIMA MLA, MUNUERA A, PEIXOTO D, GUIMAR\u00c3ES M, SILVA C. The prevalence of depression in fibromyalgia syndrome. Int J Psychiatry. 2016;21(6). Available from: https:\/\/www.polbr.med.br\/ano16\/art0616.php. [cited 2019 Jul 25]."},{"issue":"5","key":"137_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11916-005-0003-x","volume":"9","author":"K BAKER","year":"2005","unstructured":"BAKER K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep. 2005;9(5):301\u20136Available from. https:\/\/doi.org\/10.1007\/s11916-005-0003-x.","journal-title":"Curr Pain Headache Rep"},{"key":"137_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/JPR.S105892","volume":"9","author":"M DUENAS","year":"2016","unstructured":"DUENAS M, OJEDA B, SALAZAR A, MICO JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. JPR. 2016;9:457\u201367Available from. https:\/\/doi.org\/10.2147\/JPR.S105892.","journal-title":"JPR"},{"issue":"11","key":"137_CR32","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/archinte.164.3.298","volume":"63","author":"BY THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA UPDATE EXPERT PANEL","year":"2015","unstructured":"BY THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA UPDATE EXPERT PANEL. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227\u201346Available from. https:\/\/doi.org\/10.1001\/archinte.164.3.298.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"137_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3344\/kjp.2018.31.3.147","volume":"31","author":"A BIDARI","year":"2018","unstructured":"BIDARI A, PARSA BG, GHALEHBAGHI B. Challenges in fibromyalgia diagnosis : from meaning of symptoms to fibromyalgia labeling. Korean J Pain. 2018;31(3):147\u201354. https:\/\/doi.org\/10.3344\/kjp.2018.31.3.147.","journal-title":"Korean J Pain"},{"key":"137_CR34","doi-asserted-by":"publisher","unstructured":"POLLOCK A, CAMPBELL P, HUNT H, ESTCOURT L, Brunton G. Selecting and implementing overview methods: implications from five exemplary overviews. Syst Rev. 2017Available from. https:\/\/doi.org\/10.1186\/s13643-017-0534-3.","DOI":"10.1186\/s13643-017-0534-3"},{"key":"137_CR35","doi-asserted-by":"publisher","unstructured":"LI G, BHATT M, WANG M, MBUAGBAW L, SAMAAN Z, THABANE L. Enhancing primary reports of randomized controlled trials: three most common challenges and suggested solutions. Proc Natl Acad Sci. 2018;115(11):2595\u20139. Available from: https:\/\/doi.org\/10.1073\/pnas.1708286114.","DOI":"10.1073\/pnas.1708286114"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-020-00137-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:11:52Z","timestamp":1625699512000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-020-00137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1186\/s42358-020-00137-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}